Eli Lilly may have had a rough quarter after being unable to meet Wall Street expectations but the company’s stock price soared after its donanemab treatment for Alzheimer's disease recently earned a Breakthrough Therapy designation from the U.S. FDA after its success in the Phase 2 clinical trial. If it succeeds, donanemab could give Eli Lilly an entry into the vast blue ocean market of Alzheimer’s Disease. The other promising drug candidate of the company is tirzepatide, a diabetes and obesity ....
